Materias dentro de su búsqueda.
Mostrando 4,721 - 4,740 Resultados de 4,918 Para Buscar '"Pfizer"', tiempo de consulta: 0.62s Limitar resultados
  1. 4721
    “…INTRODUCTION: Fin décembre 2020, les vaccins anti-Covid-19 à ARNm Comirnaty© de Pfizer-BioNTech et Moderna© de Moderna Biotech ont obtenu l’AMM conditionnelle en France. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Retour d’expérience sur la vaccination anti-Covid-19 des patients étiquetés « à risque allergique »
  2. 4722
    “…Le 12/03, il recevait sa 1(ère) dose de vaccin COVID-19 (Pfizer/BioNTech), sans réaction immédiate. Le 22/03 il développait un tableau associant: myalgies, faiblesse musculaire des membres, dysphagie, dyspnée, dysphonie et diplopie bilatérale avec rhabdomyolyse (CK 12647 U/L). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Myopathie nécrosante chez un patient atteint d’un mélanome avancé traité par immunothérapie après une vaccination contre la COVID-19
  3. 4723
    “…Falsey, MD, AstraZeneca (Individual(s) Involved: Self): Grant/Research Support; BioFire Diagnostics (Individual(s) Involved: Self): Grant/Research Support; Janssen (Individual(s) Involved: Self): Grant/Research Support; Merck, Sharpe and Dohme (Individual(s) Involved: Self): Grant/Research Support; Novavax (Individual(s) Involved: Self): Other Financial or Material Support, Paid DSMB member; Pfizer (Individual(s) Involved: Self): Grant/Research Support Kristi Williams, PhD, Janssen R&D US (Employee) Efi Gymnopoulou, MSc, Janssen Infectious Diseases BV (Employee) Arangassery Rosemary Bastian, PhD, Janssen Vaccines & Prevention BV (Employee) Joris Menten, n/a, Janssen Infectious Diseases BV (Employee) Els De Paepe, MSc, Janssen Infectious Diseases BV (Employee) Hilde de Boer, MSc, Janssen-Cilag (Employee) Sjoukje Vandenberghe, n/a, Janssen Infectious Diseases BV (Employee) Eric Chan, PhD, Janssen Global Services, LLC (Employee) Jerald Sadoff, MD, Johnson & Johnson (Employee, Shareholder) Macaya Douoguih, MD, MPH, Janssen (Employee) Benoit Callendret, PhD, Janssen Vaccines & Prevention BV (Employee) Christy Comeaux, MD, Janssen Vaccines & Prevention BV (Employee) Esther Heijnen, MD, Janssen Vaccines & Prevention BV (Employee)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    LB14. Efficacy and Immunogenicity of an Ad26.RSV.preF-based Vaccine in the Prevention of RT-PCR-confirmed RSV-mediated Lower Respiratory Tract Disease in Adults Aged ≥65 Years: A Randomized, Placebo-controlled, Phase 2b Study
  4. 4724
    “…Chemaly, MD, MPH, FACP, FIDSA, AiCuris (Grant/Research Support)Ansun Biopharma (Consultant, Grant/Research Support)Chimerix (Consultant, Grant/Research Support)Clinigen (Consultant)Genentech (Consultant, Grant/Research Support)Janssen (Consultant, Grant/Research Support)Karius (Grant/Research Support)Merck (Consultant, Grant/Research Support)Molecular Partners (Consultant, Advisor or Review Panel member)Novartis (Grant/Research Support)Oxford Immunotec (Consultant, Grant/Research Support)Partner Therapeutics (Consultant)Pulmotec (Consultant, Grant/Research Support)Shire/Takeda (Consultant, Grant/Research Support)Viracor (Grant/Research Support)Xenex (Grant/Research Support) Fareed Khawaja, MBBS, Eurofins Viracor (Research Grant or Support) Monica Slavin, MBBS,MD, F2G (Advisor or Review Panel member)Merck (Advisor or Review Panel member)Pfizer (Advisor or Review Panel member) Dimitrios P. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    22. International Multicenter Study Comparing Cancer to Non-Cancer Patients with COVID-19: Impact of Risk Factors and Treatment Modalities on Outcome
  5. 4725
    “…(Consultant)MedImmune (Consultant, Grant/Research Support)Merck (Grant/Research Support)NIH (Grant/Research Support)Novadigm (Consultant)Novartis (Consultant, Grant/Research Support)Pfizer (Grant/Research Support)Regeneron (Consultant, Grant/Research Support)sepsis diagnostics (Other Financial or Material Support, Pending patent for host gene expression signature diagnostic for sepsis.)Tetraphase (Consultant)Theravance (Consultant, Grant/Research Support, Other Financial or Material Support, Educational fees)Trius (Consultant)UpToDate (Other Financial or Material Support, Royalties)Valanbio (Consultant, Other Financial or Material Support, Stock options)xBiotech (Consultant)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1373. Racial Disparities in Clinical Characteristics and Outcomes for Methicillin Susceptible and Methicillin-Resistant Staphylococcus aureus Bacteremia
  6. 4726
    “…Of 3 482 295 individuals vaccinated with BNT162b2 (Pfizer-BioNTech), 48 developed myocarditis or myopericarditis within 28 days from the vaccination date compared with unvaccinated individuals (adjusted hazard ratio 1.34 (95% confidence interval 0.90 to 2.00); absolute rate 1.4 per 100 000 vaccinated individuals within 28 days of vaccination (95% confidence interval 1.0 to 1.8)). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study
  7. 4727
    por Molina, Josselyn Glamyr
    Publicado 2021
    “…The antibody test was performed > 14 days after the second Moderna or Pfizer vaccine dose or after the Johnson & Johnson single dose. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Anti-Spike (S) Antibody Production Post Covid-19 Vaccination after B Cell Depleting Therapy (BCDT) for Non-Hodgkin Lymphoma (NHL)
  8. 4728
    “…[Figure: see text] DISCLOSURES: Garcia-Gutiérrez:  Pfizer: Research Funding; Incyte: Consultancy; Novartis: Consultancy; Bristol-Myers Squibb: Consultancy.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Characterization of the Humoral and Cellular Immune Response Against the Natural Infection By Sars-Cov-2 in Oncohematological Patients with Post-COVID19 Autologous Transplantation
  9. 4729
    “…DISCLOSURES: Lanzkron:  Teva: Current holder of individual stocks in a privately-held company; Shire: Research Funding; GBT: Research Funding; CSL Behring: Research Funding; Novo Nordisk: Consultancy; Bluebird Bio: Consultancy; Pfizer: Current holder of individual stocks in a privately-held company; Imara: Research Funding; Novartis: Research Funding.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The Telemedicine Experience for Individuals with Sickle Cell Disease
  10. 4730
    “…[Figure: see text] DISCLOSURES: Ahlstrom:  Takeda: Other: Patient Advisory; Pfizer: Other: Patient Advisory; Janssen: Other: Patient Advisory; Bristol Myers Squibb: Other: Patient Advisory.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Multiple Myeloma, Clinical Characteristics, and Increased COVID-19 Risk Using Real-World Data
  11. 4731
    “…At ages 18–64 years, the adjusted vaccine effectiveness against infection was 62·8% (95% CI 49·3–72·7) after two doses compared to unvaccinated people, for all vaccines combined, 44·8% (22·5–60·7) for the ChAdOx1 nCov-19 (Oxford–AstraZeneca) vaccine, and 71·3% (56·6–81·0) for the BNT162b2 (Pfizer–BioNTech) vaccine. In individuals aged 18 years and older, the weighted prevalence of swab positivity was 0·35% (95% CrI 0·31–0·40) if the second dose was administered up to 3 months before their swab but 0·55% (0·50–0·61) for those who received their second dose 3–6 months before their swab, compared to 1·76% (1·60–1·95) among unvaccinated individuals. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys
  12. 4732
    “…A partir de janeiro de 2021, foi iniciado a vacinação nos TAS: 70,9% vacinados com CoronaVac (Sinovac); 26,9% AstraZeneca; 0,2% Janssen; Pfizer 1,9% e 0,2% Janssen. A taxa de adesão à vacinação foi de 98,34%. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    IMPACTO DA VACINAÇÃO E DAS MEDIDAS DE PREVENÇÃO PARA COVID-19 EM TRABALHADORES DA ÁREA DA SAÚDE DE 12 HOSPITAIS DO ESTADO DE SÃO PAULO
  13. 4733
    por Fabiani, Massimo, Puopolo, Maria, Morciano, Cristina, Spuri, Matteo, Spila Alegiani, Stefania, Filia, Antonietta, D’Ancona, Fortunato, Del Manso, Martina, Riccardo, Flavia, Tallon, Marco, Proietti, Valeria, Sacco, Chiara, Massari, Marco, Da Cas, Roberto, Mateo-Urdiales, Alberto, Siddu, Andrea, Battilomo, Serena, Bella, Antonino, Palamara, Anna Teresa, Popoli, Patrizia, Brusaferro, Silvio, Rezza, Giovanni, Menniti Ippolito, Francesca, Pezzotti, Patrizio, Boros, Stefano, Rota, Maria Cristina, Bressi, Marco, Vescio, Maria Fenicia, Petrone, Daniele, Di Benedetto, Corrado, Ciervo, Alessandra, Stefanelli, Paola, Petrucci, Antonia, La Bianca, Michele, Mignuoli, Anna Domenica, Buono, Pietro, Massimiliani, Erika, Barbone, Fabio, Vairo, Francesco, Sticchi, Camilla, Cereda, Danilo, Di Furia, Lucia, Sforza, Francesco, Bassot, Annamaria, Benetollo, Pier Paolo, Pasqualini, Chiara, Bisceglia, Lucia, Palmas, Maria Antonietta, Scondotto, Salvatore, Balocchini, Emanuela, Tosti, Anna, Ruffier, Mauro, Da Re, Filippo, Odio, Camillo, Recine, Michele, Ruberto, Innocenza, Bisogno, Salvatore Ascione, Massimo, Miserendino, Gandolfo, Navacchia, Massimiliano, Del Frate, Beatrice, Cau, Emanuela, Baiocchi, Diego, Fusco, Danilo, Gallo, Domenico, Marchetti, Maria Rosa, Spazzafumo, Liana, Malatesta, Raffaele, Fanolla, Antonio, Conforti, Diego, Trentini, Carlo, Ruggeri, Antonino, Ladalardo, Concetta, Albano, Nehludoff, Corona, Marco, Lombardi, Paolo, Iacono, Massimo, Angori, Paolo Bruno, Belardinelli, Andrea, Solfiti, Milena, Fioraso, Stefano, Poma, Chiara, Raccanello, Nadia
    Publicado 2022
    “…PARTICIPANTS: 33 250 344 people aged ≥16 years who received a first dose of BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccine and did not have a previous diagnosis of SARS-CoV-2 infection. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study
  14. 4734
    “…In the most recent time window centred on July 29, 2021, the efficacy of two doses was 91% (95% CI 87–94) for the ChAdOx1 vaccine and 92% (88–95) for mRNA (Pfizer or Moderna) vaccines. The efficacy of the ChAdOx1 vaccine against severe COVID-19 declined with time since second dose to 69% (95% CI 52–80) at 20 weeks from second dose. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study
  15. 4735
    “…Vaccine effectiveness was calculated after primary immunization with two doses of BNT162b2 (Pfizer–BioNTech), ChAdOx1 nCoV-19 (AstraZeneca), or mRNA-1273 (Moderna) vaccine and after a booster dose of BNT162b2, ChAdOx1 nCoV-19, or mRNA-1273. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
  16. 4736
    por Liu, Xinxue, Munro, Alasdair P S, Feng, Shuo, Janani, Leila, Aley, Parvinder K, Babbage, Gavin, Baxter, David, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna, Dejnirattisai, Wanwisa, Dodd, Kate, Enever, Yvanne, Qureshi, Ehsaan, Goodman, Anna L., Green, Christopher A, Harndahl, Linda, Haughney, John, Hicks, Alexander, van der Klaauw, Agatha A., Kwok, Jonathan, Libri, Vincenzo, Llewelyn, Martin J, McGregor, Alastair C, Minassian, Angela M., Moore, Patrick, Mughal, Mehmood, Mujadidi, Yama F, Holliday, Kyra, Osanlou, Orod, Osanlou, Rostam, Owens, Daniel R, Pacurar, Mihaela, Palfreeman, Adrian, Pan, Daniel, Rampling, Tommy, Regan, Karen, Saich, Stephen, Serafimova, Teona, Saralaya, Dinesh, Screaton, Gavin R, Sharma, Sunil, Sheridan, Ray, Sturdy, Ann, Supasa, Piyada, Thomson, Emma C, Todd, Shirley, Twelves, Chris, Read, Robert C., Charlton, Sue, Hallis, Bassam, Ramsay, Mary, Andrews, Nick, Lambe, Teresa, Nguyen-Van-Tam, Jonathan S, Cornelius, Victoria, Snape, Matthew D, Faust, Saul N
    Publicado 2022
    “…In the participants who had two initial doses of ChAdOx1 nCov-19 (Oxford-AstraZeneca; hereafter referred to as ChAd), schedules using mRNA vaccines as third dose have the highest anti-spike IgG at D84 (e.g. geometric mean concentration of 8674 ELU/ml (95% CI: 7461–10,085) following ChAd/ChAd/BNT162b2 (Pfizer-BioNtech, hearafter referred to as BNT)). However, in people who had two initial doses of BNT there was no significant difference at D84 in people given ChAd versus BNT (geometric mean ratio (GMR) of 0.95 (95%CI: 0.78, 1.15). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.
  17. 4737
    “…We used multivariable logistic regression to estimate the effectiveness of one, two, and three doses of mRNA-based COVID-19 vaccine (BNT162b2 [Pfizer–BioNTech], or mRNA-1273 [Moderna]) among individuals at the time of SARS-CoV-2 testing. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis
  18. 4738
    “…Fifty-five percent of vaccinated participants received Pfizer-BioNTech’s mRNA vaccine, 37% received Moderna’s mRNA vaccine, and 7% received the Johnson & Johnson/Janssen vaccine (J&J). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Covid-19 vaccination and menstrual cycle length in the Apple Women’s Health Study
  19. 4739
    “…BACKGROUND: There is a scarcity of research regarding the effectiveness of the mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in patients taking immunosuppressant medications, and no data are published to date pertaining to their effectiveness against omicron (B.1.1.529) variant SARS-CoV-2 infection and hospitalisation. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    COVID-19 vaccine effectiveness against omicron (B.1.1.529) variant infection and hospitalisation in patients taking immunosuppressive medications: a retrospective cohort study
  20. 4740
    por Ducrot, Françoise, Tardy, Grégoire
    Publicado 2022
    “…En mai, après confirmation des livraisons de doses de vaccins du laboratoire Pfizer BioNtech par l’ARS, le SSTRN, fort d’équipes aguerries à l’adaptation de leur environnement professionnel depuis notamment quatorze mois, lance le projet d’ouverture d’un centre de vaccination. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Expérience du centre de vaccination du SSTRN en période COVID
Herramientas de búsqueda: RSS